Alnylam to present data from the apollo-b phase 3 study of patisiran in patients with attr amyloidosis with cardiomyopathy at the 18th international symposium on amyloidosis

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, announced today that the company will present data from the apollo-b phase 3 study of patisiran, an investigational rnai therapeutic in development for the treatment of transthyretin-mediated (attr) amyloidosis with cardiomyopathy, during a late-breaker session at the 18th international symposium on amyloidosis (isa) on september 8, 2022. the company announced positive topline
ALNY Ratings Summary
ALNY Quant Ranking